Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiraMSC-FS-001 in Elderly Subjects With Mild to Moderate Frailty Syndrome
NCT07705464Phase 1Not yet recruiting
- Sponsor
- Miracle Biomedical
- Start
- Dec 2026
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label trial of MiraMSC-FS-001 in frailty syndrome (2 cohorts), sponsored by Miracle Biomedical. Primary endpoints: Maximum Feasible Dose, Dose-limiting toxicities and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
MiraMSC-FS-001
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT07705464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705464.